Market News AIOpen the app

Ascentage Pharma said its drug lisaftoclax will be covered in China's 2026 National Reimbursement Drug List, and olverembatinib's coverage was renewed.

ProductRead the original at globenewswire.com
Good for AAPG

Ascentage Pharma now has coverage for all approved uses of lisaftoclax and olverembatinib in China. This should improve access and affordability, though the new terms start in 2027.

AAPG · Ascentage Pharma

AI read · Good for AAPG

The AI's read

Wider coverage can help more patients in China obtain these medicines and may support sales. The source gives no estimate of how many patients will use them, so the size of any sales gain is unknown.

Get alerts for AAPG

Follow Ascentage Pharma (AAPG) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AAPG
Free on the App Store and Google Play, or on the web.